Tag Archives: PD-1

No account yet? Register

industry & policy

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors

Immune-Onc Therapeutics, Inc. announced that the first patient has been dosed in the company’s first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) for the treatment of solid tumors.

[Immune-Onc Therapeutics, Inc.]

[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]

Press Release

No account yet? Register

Prognostic Implications of Tumor-Infiltrating T Cells in Early-Stage Endometrial Cancer

The proportion of T cells and their subpopulations were associated with clinicopathological features and relapse-free survival outcomes. CD3+ CD4+ infiltrates were more abundant in the patients with higher grade or non-endometrioid histology.

[Modern Pathology]

[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]

Abstract

No account yet? Register

Single-Cell Profiling Reveals the Importance of CXCL13/CXCR5 Axis Biology in Lymphocyte-Rich Classic Hodgkin Lymphoma

Researchers examined the immune cell profile of eight cell suspension samples of Lymphocyte-rich classic Hodgkin lymphoma (LR-CHL) in comparison to 20 samples of the mixed cellularity and nodular sclerosis subtypes of CHL.

[Proceedings of the National Academy of Sciences of the United States of America]

[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]

No account yet? Register

Leukemic Progenitor Cells Enable Immunosuppression and Post-Chemotherapy Relapse via IL-36–Inflammatory Monocyte Axis

Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.

[Science Advances]

[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]

No account yet? Register

Heterogeneous Distribution of PD-L1 Expression in the IASLC/ATS/ERS Classification of Lung Adenocarcinoma

94 lung adenocarcinoma cases were reviewed in the Third Affiliated Hospital of Soochow University from January to December 2019. PD-L1 (DAKO 22C3) was used to test the PD-L1 expression in lung cancer tissue.

[International Journal of Clinical Oncology]

[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]

Abstract

No account yet? Register

industry & policy

Surface Oncology Announces New Randomized Phase II Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche

Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase II clinical study evaluating SRF388, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.

[Surface Oncology]

[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]

Press Release

No account yet? Register

Antigen Presentation by Lung Epithelial Cells Directs CD4⁺T_RM Cell Function and Regulates Barrier Immunity

Researchers reported that lung epithelial cells, including distinct surfactant protein C (SPC)^lowMHC^high epithelial cells, functioned as anatomically-segregated and temporally-dynamic antigen presenting cells.

[Nature Communications]

[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]

No account yet? Register

BET Protein Degradation Triggers DR5-Mediated Immunogenic Cell Death to Suppress Colorectal Cancer and Potentiate Immune Checkpoint Blockade

Researchers found that inducing the degradation of bromodomain and extra-terminal domain (BET) proteins by the proteolysis targeting chimeras approach potently suppressed the growth of colorectal cancer including patient-derived tumors.

[Oncogene]

[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]

Abstract

No account yet? Register

Therapeutic Effectiveness and Safety of Sintilimab-Dominated Triple Therapy in Unresectable Hepatocellular Carcinoma

Scientists evaluated the effectiveness and safety of sintilimab, a programmed cell death protein-1 blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in patients with unresectable hepatocellular carcinoma, compared with sintilimab monotherapy and sintilimab-sorafenib duotherapy.

[Scientific Reports]

[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]

No account yet? Register

Full Article Graphical Abstract

Atovaquone-HSA Nano-Drugs Enhance the Efficacy of PD-1 Blockade Immunotherapy by Alleviating Hypoxic Tumor Microenvironment

The authors exploited atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia.

[Journal of Nanobiotechnology]

[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]